Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to produce defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85% protection when immunised four weeks before birth
• Maternal antibodies passed through placenta safeguard newborns from day one
• Protection achievable with 2-week gap before premature birth
• Vaccination in the third trimester still offers significant infant protection

Persuasive evidence from the latest research

The performance of the pregnancy RSV vaccine has been established through a thorough investigation conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that half-year window, providing robust and representative information of the vaccine’s actual performance. The study’s conclusions have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The scope of this study provides healthcare professionals and expectant parents with assurance in the vaccine’s established performance across different groups and contexts.

The results reveal a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference underscores the vaccine’s vital importance in protecting against serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.

Study methodology and scope

The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology captured practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when given across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.

Comprehending RSV and the hazards

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.

The infection triggers deep inflammation in the lungs and airways, making it dangerously difficult for infected babies to breathe and feed adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they work to get sufficient oxygen into their damaged lungs. Whilst most newborns get better with palliative treatment, a modest yet notable group succumb from respiratory syncytial virus complications annually, making immunisation programmes a vital health service imperative for defending the most vulnerable and youngest individuals in the population.

• RSV triggers lung inflammation, resulting in serious respiratory problems in infants
• Nearly 50% of infants contract the virus in their first few months of life
• Symptoms range from mild colds to serious chest infections that threaten life needing hospital treatment
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• Small numbers of babies succumb to RSV related complications annually in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies through the placenta.

The communication from public health bodies stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of severe infection.

Regional differences in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences reflect variations in medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts launching diverse outreach initiatives to connect with expectant mothers
• Regional disparities in vaccine uptake rates in different parts of England require targeted improvement
• Regional health providers adapting programmes to suit specific population needs

Real-world impact and parent viewpoints

The vaccine’s remarkable effectiveness provides concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this safeguarding intervention, the 80% drop in admissions means thousands of infants spared from severe infection. Parents no more face the upsetting situation of watching their newborns labour to breathe or struggle to eat, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal respiratory health, providing expectant mothers a proactive tool to protect their most vulnerable children during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s availability carries significant emotional significance. His mother’s advocacy for the jab highlights the profound consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to pregnant women during their third trimester, transforming what was once an predictable seasonal threat into a controllable health concern.